Compass Therapeutics, Inc.
CMPXCompass Therapeutics, Inc. in brief
Compass Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $137 M on 29 October 2026, which makes it the 17,617th largest listed company in the world and the 3,354th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $66 M. It employs about 39 people and Thomas J. Schuetz is its chief executive. Its shares trade under the symbol CMPX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Compass Therapeutics, Inc.
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data.
From the company's annual report filed with the US SEC: read the report
Compass Therapeutics, Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- ✎Renamed Compass Therapeutics, Inc.Formerly Olivia Ventures, Inc..
Events of Compass Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,393 (Jan 2022) · #2,322 (Dec 2022) · #3,077 (Jul 2023) · #3,255 (Jan 2024) · #874 (Mar 2026) · #2,661 (Aug 2026) · #3,268 (Oct 2026) · #3,358 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.7×
- Free cash flow yield
- -35.9%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -33.8%
- Liabilities / assets
- 10.4%
- Net debt
- $-145M
- R&D / revenue
- 4981.2%
- Revenue per employee
- $0 K
- Profit per employee
- $-1.7 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-73M | $-66M | — |
| Dec 2024 | $1M | — | $-57M | $-49M | -5809.4% |
| Dec 2023 | — | — | $-50M | $-42M | — |
| Dec 2022 | — | — | $-42M | $-39M | — |
| Dec 2021 | — | — | $-82M | $-82M | — |
| Dec 2020 | — | — | $-28M | $-30M | — |
| Dec 2019 | — | — | $-34M | $-35M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-49M | $0M | $-49M | — | — |
| Dec 2024 | $-45M | $0M | $-45M | — | — |
| Dec 2023 | $-41M | $0M | $-41M | — | — |
| Dec 2022 | $-34M | $0M | $-34M | — | — |
| Dec 2021 | $-20M | $2M | $-21M | $-1.31 | — |
| Dec 2020 | $-27M | $0M | $-27M | $-0.96 | — |
| Dec 2019 | $-32M | $0M | $-32M | $-5.19 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-27M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Sep 22, 20268-KCurrent reportRegulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jul 1, 20268-KCurrent reportRegulation FD disclosure
- Jun 23, 20268-KCurrent reportBylaws amended
- Jun 11, 20268-KCurrent reportShareholder vote
- May 5, 202610-QQuarterly report · period to Mar 2026
- May 5, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Apr 27, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Compass Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-73 M
- Net income
- $-66 M
For year ending December-2025
Balance sheet
- Total assets
- $220 M
- Total liabilities
- $23 M
- Total equity
- $197 M
As of December-2025
Top 100 institutional investors in Compass Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Tang Capital Management LLC | 17,990,782 | 0 (0.00%) | 9.99% | $19 M | Nov 16, 2026 |
| 2 | Orbimed Advisors LLC | 15,219,994 | 0 (0.00%) | 8.45% | $16 M | Nov 16, 2026 |
| 3 | Montanova Capital, LLC | 14,326,988 | +225,829 (+1.60%) | 7.96% | $15 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 11,394,556 | +112,775 (+1.00%) | 6.33% | $12 M | Nov 13, 2026 |
| 5 | Enavate Sciences GP, LLC | 7,788,150 | 0 (0.00%) | 4.32% | $8 M | Nov 16, 2026 |
| 6 | State Street Corp | 7,737,938 | -2,215,715 (-22.26%) | 4.30% | $8 M | Nov 12, 2026 |
| 7 | Palo Alto Investors LP | 7,148,673 | +1,316,860 (+22.58%) | 3.97% | $7 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 5,994,782 | -124,000 (-2.03%) | 3.33% | $6 M | Nov 13, 2026 |
| 9 | Millennium Management LLC | 4,686,422 | -26,825 (-0.57%) | 2.60% | $5 M | Nov 16, 2026 |
| 10 | Qube Research & Technologies Ltd | 4,170,894 | +483,405 (+13.11%) | 2.32% | $4 M | Nov 13, 2026 |
| 11 | Geode Capital Management, LLC | 3,644,115 | -171,074 (-4.48%) | 2.02% | $4 M | Nov 6, 2026 |
| 12 | Rock Springs Capital Management LP | 3,524,929 | 0 (0.00%) | 1.96% | $4 M | Nov 16, 2026 |
| 13 | Vivo Capital, LLC | 3,423,547 | -4,333,513 (-55.87%) | 1.90% | $4 M | Nov 13, 2026 |
| 14 | Goldman Sachs Group Inc | 3,394,871 | -136,129 (-3.86%) | 1.89% | $4 M | Nov 16, 2026 |
| 15 | Blue Owl Capital Holdings LP | 3,154,076 | -470,000 (-12.97%) | 1.75% | $3 M | Nov 13, 2026 |
| 16 | HRT Financial LP | 2,662,384 | +2,492,282 (+1465.17%) | 1.48% | $3 M | Nov 13, 2026 |
| 17 | Acadian Asset Management LLC | 2,635,682 | +1,474,451 (+126.97%) | 1.46% | $3 M | Nov 9, 2026 |
| 18 | Citadel Advisors LLC | 2,138,002 | -1,432,672 (-40.12%) | 1.19% | $2 M | Nov 16, 2026 |
| 19 | Vanguard Portfolio Management LLC | 2,077,875 | -1,693,157 (-44.90%) | 1.15% | $2 M | Nov 13, 2026 |
| 20 | AQR Capital Management LLC | 1,975,133 | -1,534,004 (-43.71%) | 1.10% | $2 M | Nov 16, 2026 |
| 21 | Fisher Asset Management, LLC | 1,945,821 | +553,931 (+39.80%) | 1.08% | $2 M | Nov 6, 2026 |
| 22 | FMR LLC | 1,797,306 | +585,110 (+48.27%) | 1.00% | $2 M | Nov 10, 2026 |
| 23 | D. E. Shaw & Co., Inc. | 1,746,286 | +1,541,799 (+753.98%) | 0.97% | $2 M | Nov 16, 2026 |
| 24 | Marshall Wace, LLP | 1,707,238 | +1,372,369 (+409.82%) | 0.95% | $2 M | Nov 13, 2026 |
| 25 | Birchview Capital, LP | 1,575,000 | -100,000 (-5.97%) | 0.87% | $2 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Morgan Stanley | 1,494,654 | +759,468 (+103.30%) | 0.83% | $2 M | Nov 13, 2026 |
| 27 | Algert Global LLC | 1,458,278 | +1,150,168 (+373.30%) | 0.81% | $2 M | Nov 17, 2026 |
| 28 | Squarepoint Ops LLC | 1,389,796 | +382,289 (+37.94%) | 0.77% | $1 M | Nov 9, 2026 |
| 29 | Arrowstreet Capital, Limited Partnership | 1,208,004 | New | 0.67% | $1 M | Nov 13, 2026 |
| 30 | Northern Trust Corp | 1,089,228 | -51,686 (-4.53%) | 0.60% | $1 M | Nov 16, 2026 |
| 31 | Vanguard Fiduciary Trust Co | 973,188 | -27,750 (-2.77%) | 0.54% | $1 M | Nov 13, 2026 |
| 32 | Royce & Associates LP | 888,393 | -448,387 (-33.54%) | 0.49% | $1 M | Nov 9, 2026 |
| 33 | Dimensional Fund Advisors LP | 855,724 | +314,546 (+58.12%) | 0.48% | $1 M | Nov 4, 2026 |
| 34 | Susquehanna International Group, LLP | 775,923 | +467,628 (+151.68%) | 0.43% | $1 M | Nov 16, 2026 |
| 35 | KVP Capital Advisors, LP | 771,000 | 0 (0.00%) | 0.43% | $1 M | Nov 16, 2026 |
| 36 | Two Sigma Investments, LP | 769,443 | +449,131 (+140.22%) | 0.43% | $1 M | Nov 16, 2026 |
| 37 | CM Management, LLC | 750,000 | +200,000 (+36.36%) | 0.42% | $1 M | Nov 12, 2026 |
| 38 | Burkehill Global Management, LP | 700,000 | 0 (0.00%) | 0.39% | $1 M | Nov 16, 2026 |
| 39 | Connor, Clark & Lunn Investment Management Ltd. | 677,252 | +153,475 (+29.30%) | 0.38% | $1 M | Nov 10, 2026 |
| 40 | Quadrature Capital Ltd | 638,820 | +530,570 (+490.13%) | 0.35% | $1 M | Nov 13, 2026 |
| 41 | Citigroup Inc | 615,135 | -98,772 (-13.84%) | 0.34% | $1 M | Nov 4, 2026 |
| 42 | Exome Asset Management LLC | 511,084 | +234,919 (+85.06%) | 0.28% | $1 M | Nov 16, 2026 |
| 43 | Walleye Capital LLC | 492,913 | New | 0.27% | $1 M | Nov 13, 2026 |
| 44 | Bank Of America Corp /de/ | 464,382 | -102,537 (-18.09%) | 0.26% | $0 M | Nov 16, 2026 |
| 45 | Wellington Management Group LLP | 459,036 | +80,349 (+21.22%) | 0.25% | $0 M | Nov 16, 2026 |
| 46 | Jacobs Levy Equity Management, Inc | 449,301 | New | 0.25% | $0 M | Nov 16, 2026 |
| 47 | Charles Schwab Investment Management Inc | 430,889 | +127,750 (+42.14%) | 0.24% | $0 M | Nov 16, 2026 |
| 48 | UBS Group AG | 423,370 | -289,393 (-40.60%) | 0.24% | $0 M | Nov 10, 2026 |
| 49 | Nuveen, LLC | 387,282 | -623,280 (-61.68%) | 0.22% | $0 M | Nov 10, 2026 |
| 50 | Caption Management, LLC | 385,471 | +121,894 (+46.25%) | 0.21% | $0 M | Nov 16, 2026 |
| 51 | Gsa Capital Partners LLP | 373,703 | +303,524 (+432.50%) | 0.21% | $0 M | Nov 16, 2026 |
| 52 | Bank of New York Mellon Corp | 351,830 | +798 (+0.23%) | 0.20% | $0 M | Nov 5, 2026 |
| 53 | Natixis | 310,800 | +13,085 (+4.40%) | 0.17% | $0 M | Nov 6, 2026 |
| 54 | Jpmorgan Chase & Co | 303,853 | -485,546 (-61.51%) | 0.17% | $0 M | Nov 12, 2026 |
| 55 | XTX Topco Ltd | 290,710 | +73,225 (+33.67%) | 0.16% | $0 M | Nov 16, 2026 |
| 56 | Point72 Asset Management, L.P. | 289,033 | -397,544 (-57.90%) | 0.16% | $0 M | Nov 16, 2026 |
| 57 | Voleon Capital Management LP | 265,130 | New | 0.15% | $0 M | Nov 16, 2026 |
| 58 | Acuta Capital Partners, LLC | 251,001 | -344,212 (-57.83%) | 0.14% | $0 M | Nov 16, 2026 |
| 59 | Vestcor Inc | 239,888 | New | 0.13% | $0 M | Nov 12, 2026 |
| 60 | Alps Advisors Inc | 236,892 | +54,115 (+29.61%) | 0.13% | $0 M | Nov 3, 2026 |
| 61 | Rafferty Asset Management, LLC | 208,702 | +18,576 (+9.77%) | 0.12% | $0 M | Nov 13, 2026 |
| 62 | Panagora Asset Management Inc | 202,635 | -19,544 (-8.80%) | 0.11% | $0 M | Nov 12, 2026 |
| 63 | DV Equities, LLC | 193,034 | -40,032 (-17.18%) | 0.11% | $0 M | Nov 16, 2026 |
| 64 | Seven Fleet Capital Management LP | 193,034 | -40,032 (-17.18%) | 0.11% | $0 M | Nov 16, 2026 |
| 65 | Creative Planning | 161,774 | -21,067 (-11.52%) | 0.09% | $0 M | Nov 2, 2026 |
| 66 | Canada Pension Plan Investment Board | 160,900 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 67 | Rhumbline Advisers | 157,501 | -943 (-0.60%) | 0.09% | $0 M | Nov 10, 2026 |
| 68 | Virtus Investment Advisers, LLC | 156,322 | -4,859 (-3.01%) | 0.09% | $0 M | Nov 12, 2026 |
| 69 | HSBC Holdings PLC | 142,964 | New | 0.08% | $0 M | Nov 16, 2026 |
| 70 | Alliancebernstein L.P. | 129,310 | -32,570 (-20.12%) | 0.07% | $0 M | Nov 16, 2026 |
| 71 | Caitong International Asset Management Co., Ltd | 123,621 | +104,320 (+540.49%) | 0.07% | $0 M | Oct 29, 2026 |
| 72 | ADAR1 Capital Management, LLC | 119,500 | -2,632 (-2.16%) | 0.07% | $0 M | Nov 16, 2026 |
| 73 | Deutsche Bank AG\ | 114,236 | -20,114 (-14.97%) | 0.06% | $0 M | Nov 6, 2026 |
| 74 | Ameriprise Financial Inc | 107,820 | New | 0.06% | $0 M | Nov 16, 2026 |
| 75 | Ieq Capital, LLC | 107,474 | -15,474 (-12.59%) | 0.06% | $0 M | Nov 10, 2026 |
| 76 | Group One Trading LLC | 107,068 | +25,511 (+31.28%) | 0.06% | $0 M | Nov 10, 2026 |
| 77 | Price T Rowe Associates Inc /MD/ | 104,251 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 78 | State of Alaska, Department of Revenue | 100,000 | New | 0.06% | $0 M | Oct 15, 2026 |
| 79 | Russell Investments Group, Ltd. | 95,084 | +44,579 (+88.27%) | 0.05% | $0 M | Nov 6, 2026 |
| 80 | Aigen Investment Management, LP | 79,568 | New | 0.04% | $0 M | Nov 16, 2026 |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 78,736 | -3,723 (-4.51%) | 0.04% | $0 M | Nov 16, 2026 |
| 82 | Brevan Howard Capital Management LP | 77,876 | +67,674 (+663.34%) | 0.04% | $0 M | Nov 16, 2026 |
| 83 | Mariner, LLC | 77,260 | -95,561 (-55.29%) | 0.04% | $0 M | Nov 12, 2026 |
| 84 | BNP Paribas Financial Markets | 76,128 | +40,497 (+113.66%) | 0.04% | $0 M | Nov 12, 2026 |
| 85 | Profund Advisors LLC | 73,294 | -21,915 (-23.02%) | 0.04% | $0 M | Oct 29, 2026 |
| 86 | Orion Porfolio Solutions, LLC | 73,263 | -140,600 (-65.74%) | 0.04% | $0 M | Nov 12, 2026 |
| 87 | IMC-Chicago, LLC | 69,791 | New | 0.04% | $0 M | Nov 5, 2026 |
| 88 | Invesco Ltd. | 64,043 | -5,775 (-8.27%) | 0.04% | $0 M | Nov 12, 2026 |
| 89 | Vanguard Global Advisers, LLC | 61,845 | +687 (+1.12%) | 0.03% | $0 M | Nov 13, 2026 |
| 90 | Los Angeles Capital Management LLC | 60,805 | -44,308 (-42.15%) | 0.03% | $0 M | Nov 12, 2026 |
| 91 | Barclays PLC | 53,983 | +3,586 (+7.12%) | 0.03% | $0 M | Nov 6, 2026 |
| 92 | MetLife Investment Management, LLC | 53,434 | -17,987 (-25.18%) | 0.03% | $0 M | Nov 16, 2026 |
| 93 | WINTON GROUP Ltd | 52,400 | +27,500 (+110.44%) | 0.03% | $0 M | Nov 12, 2026 |
| 94 | Spark Investment Management LLC | 44,000 | New | 0.02% | $0 M | Nov 13, 2026 |
| 95 | Graham Capital Management, L.P. | 43,878 | +21,021 (+91.97%) | 0.02% | $0 M | Nov 16, 2026 |
| 96 | Mercer Global Advisors Inc /adv | 43,745 | -62,825 (-58.95%) | 0.02% | $0 M | Nov 16, 2026 |
| 97 | Pale Fire Capital SE | 42,543 | New | 0.02% | $0 M | Nov 13, 2026 |
| 98 | LPL Financial LLC | 39,681 | +8,211 (+26.09%) | 0.02% | $0 M | Nov 6, 2026 |
| 99 | Manufacturers Life Insurance Company, The | 38,926 | -29,291 (-42.94%) | 0.02% | $0 M | Nov 13, 2026 |
| 100 | Tower Research Capital LLC (TRC) | 37,252 | +29,778 (+398.42%) | 0.02% | $0 M | Nov 16, 2026 |
Mutual funds holding Compass Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 6.84 M | $15 M | 3.8% | 0.14% | +86% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 4.19 M | $9 M | 2.3% | <0.01% | −0.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.46 M | $8 M | 1.9% | <0.01% | +9.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.79 M | $4 M | 1.00% | <0.01% | +4.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.43 M | $3 M | 0.79% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.21 M | $3 M | 0.67% | 0.02% | +132% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 1.12 M | $2 M | 0.62% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 798,947 | $2 M | 0.44% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 962,801 | $2 M | 0.53% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 775,001 | $2 M | 0.43% | 0.10% | new | Jun 30, 2026 |
| 🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB | 741,730 | $2 M | 0.41% | 0.43% | +88% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP | 731,677 | $2 M | 0.41% | 0.18% | +119% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 664,018 | $2 M | 0.37% | <0.01% | +2.4% | May 31, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 719,590 | $2 M | 0.40% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 589,517 | $1 M | 0.33% | 0.08% | +120% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 495,884 | $1 M | 0.28% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 440,826 | $1 M | 0.24% | 0.06% | +36% | Jun 30, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 400,227 | $1 M | 0.22% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P. | 416,737 | $1 M | 0.23% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 325,460 | $1 M | 0.18% | 0.05% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP | 323,411 | $1 M | 0.18% | 0.17% | +108% | Jun 30, 2026 |
| 🇸🇪 HealthInvest Small & Mid Cap HealthcareAtle Fund Management AB | 306,863 | $1 M | 0.17% | 0.53% | +69% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 278,340 | $1 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 322,390 | $1 M | 0.18% | <0.01% | +14% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 235,188 | $1 M | 0.13% | <0.01% | +5.8% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 243,131 | $1 M | 0.14% | <0.01% | +2.4% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 221,492 | $0 M | 0.12% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 211,802 | $0 M | 0.12% | 0.17% | no change | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 232,413 | $0 M | 0.13% | 0.09% | +10% | Jul 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 185,633 | $0 M | 0.10% | 0.27% | +17% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 183,040 | $0 M | 0.10% | 0.02% | +144% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 166,283 | $0 M | 0.09% | <0.01% | +2041% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 143,605 | $0 M | 0.08% | <0.01% | +2.1% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 158,719 | $0 M | 0.09% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 143,997 | $0 M | 0.08% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 109,310 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP | 106,692 | $0 M | 0.06% | 0.17% | — | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 121,096 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 108,322 | $0 M | 0.06% | <0.01% | +24% | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 37,706 | $0 M | 0.02% | 0.12% | — | Mar 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 101,119 | $0 M | 0.06% | <0.01% | +254% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 85,940 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Optimize Strategy Index ETFSound Capital Solutions, LLC | 80,160 | $0 M | 0.04% | 0.06% | −0.3% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 80,059 | $0 M | 0.04% | 0.05% | −14% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 79,750 | $0 M | 0.04% | <0.01% | +96% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 73,690 | $0 M | 0.04% | <0.01% | +112% | Jun 30, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 73,074 | $0 M | 0.04% | 0.01% | −6.7% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 72,192 | $0 M | 0.04% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 66,295 | $0 M | 0.04% | 0.06% | −11% | May 31, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 70,331 | $0 M | 0.04% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 64,680 | $0 M | 0.04% | <0.01% | +1.3% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 64,580 | $0 M | 0.04% | <0.01% | −1.2% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 69,505 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 78,857 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 67,910 | $0 M | 0.04% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 64,864 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 51,859 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 62,629 | $0 M | 0.03% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 65,246 | $0 M | 0.04% | 0.06% | — | Apr 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 46,665 | $0 M | 0.03% | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 46,574 | $0 M | 0.03% | 0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 57,805 | $0 M | 0.03% | <0.01% | +7.5% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 43,100 | $0 M | 0.02% | <0.01% | −6.1% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 42,214 | $0 M | 0.02% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 36,349 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 33,831 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 33,428 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 32,837 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 37,125 | $0 M | 0.02% | <0.01% | −27% | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 36,781 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 27,658 | $0 M | 0.02% | 0.02% | +58% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 29,258 | $0 M | 0.02% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 33,008 | $0 M | 0.02% | <0.01% | −50% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 28,641 | $0 M | 0.02% | <0.01% | +22% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 27,304 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 25,867 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 23,500 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 24,537 | $0 M | 0.01% | 0.01% | +6.5% | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 20,577 | $0 M | 0.01% | <0.01% | +14% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 20,280 | $0 M | 0.01% | <0.01% | +128% | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 20,090 | $0 M | 0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 19,996 | $0 M | 0.01% | <0.01% | +31% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 20,730 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 17,850 | $0 M | <0.01% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 19,635 | $0 M | 0.01% | <0.01% | +706% | Jul 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 16,306 | $0 M | <0.01% | 0.01% | −5.4% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 16,228 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 13,853 | $0 M | <0.01% | <0.01% | +1.5% | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 13,678 | $0 M | <0.01% | <0.01% | +29% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 13,219 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 14,806 | $0 M | <0.01% | <0.01% | +7.8% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 14,593 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 11,073 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 13,305 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 State Street SPDR Portfolio MSCI Global Stock Market ETFSSGA Funds Management, Inc. | 11,048 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 10,733 | $0 M | <0.01% | <0.01% | −5.0% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 10,621 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 11,915 | $0 M | <0.01% | <0.01% | +162% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 9,700 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 9,219 | $0 M | <0.01% | <0.01% | +14% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Compass Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Neil LernerChief Accounting Officer | Buy | +10,000 | $0.590 | $6 K | 430,000 | Form 4 |
| filed | Neil LernerChief Accounting Officer | Buy | +20,000 | $0.920 | $18 K | 420,000 | Form 4 |
| filed | Neil LernerChief Accounting Officer | Buy | +2,500 | $1.140 | $3 K | 400,000 | Form 4 |
| filed | Neil LernerChief Accounting Officer | Buyamended | +15,000 | $1.890 | $28 K | 397,500 | Form 4/A |
| filed | Jonathan AndermanGeneral Counsel | Buyamended | +25,000 | $1.890 | $47 K | 196,000 | Form 4/A |
| filed | Jonathan AndermanGeneral Counsel | Grant or award | +25,000 | $1.890 | $47 K | 196,000 | Form 4 |
| filed | Neil LernerChief Accounting Officer | Grant or award | +15,000 | $1.890 | $28 K | 397,500 | Form 4 |
| filed | Thomas J. SchuetzCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | -36,687 | $6.520 | $239 K | 6.60 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Compass Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-04-27 11:25 UTC, code T3, resumed 12:00 UTC
Fails to deliver
- : 31,258 shares at $0.76
- : 716 shares at $0.80
- : 165,625 shares at $0.84
- : 106,430 shares at $0.90
- : 11,592 shares at $0.86
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Compass Therapeutics, Inc. scorecard#
Passes 2 of the 10 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-35.9%Free cash flow is -35.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$66 M-$66 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$66 MNet income -$66 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-41.3%-41.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities15.0×Current ratio 15.02 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Compass Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0−100%— | 0.9—100% | 0—— | — | — | — | — | |
| Research and development | 56+32.2%— | 42+11.1%4981% | 38+27.1%— | 30+47.5%— | 20+36.5%— | 15−33.6%— | 22—— | |
| General and administrative | 17+11.5%— | 15+23.6%1780% | 12+5.0%— | 12+6.7%— | 11−15.3%— | 13+11.2%— | 12—— | |
| Operating expenses | 73+26.7%— | 57+14.1%6762% | 50+20.9%— | 42−49.1%— | 82+194%— | 28−18.3%— | 34—— | |
| Operating income | −73—— | −57—−6662% | −50—— | −42—— | −82—— | −28—— | −34—— | |
| Interest and finance income | 6.4−12.3%— | 7.3−7.6%859% | 7.9r7.9+235%— | 2.4+8038%— | 0.0−67.0%— | 0.1−88.2%— | 0.7—— | |
| Interest expense and finance costs | — | — | — | 0−100%— | 0.4−59.3%— | 0.9−26.1%— | 1.2—— | |
| Other non-operating income (expense) | 6.4−12.4%— | 7.3−7.9%853% | 7.9+224%— | 2.4—— | −0.3—— | −1.7—— | −0.6—— | |
| Income before tax | — | — | −42—— | −39—— | −82—— | −29—— | −35—— | |
| Income tax | 0—— | 0—0.0% | 0—— | 0—— | 0−100%— | 0.0−64.8%— | 0.1—— | |
| Net income including minority interests | — | — | — | — | −82—— | −30—— | −35—— | |
| Net income attributable to shareholders | −66—— | −49—−5809% | −42—— | −39—— | −82—— | −30—— | −35—— | |
| Earnings per share, basic | -0.42—— | -0.36—— | -0.33—— | -0.37—— | -1.31—— | -0.96—— | -5.19—— | |
| Earnings per share, diluted | — | — | — | — | -1.31—— | -0.96—— | -5.19—— | |
| Shares, weighted average (basic) | 158+14.8%— | 137+8.2%— | 127+20.8%— | 105+67.3%— | 63—— | — | — | |
| Shares, weighted average (diluted) | — | 137—— | — | — | 63+104%— | 31+360%— | 6.7—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 31−29.5%14.0% | 43+79.5%31.0% | 24−30.7%15.4% | 35−75.8%17.5% | 145+207%94.0% | 47+86.0%90.7% | 25r0.0—83.3% | |
| Short-term investments | 178+114%81.2% | 83−35.1%59.3% | 128−15.4%81.7% | 152—76.0% | 0—0.0% | — | — | |
| Other current assets | 0.9−84.9%0.4% | 6.0+325%4.3% | 1.4−82.6%0.9% | 8.2+216%4.1% | 2.6−17.1%1.7% | 3.1+234%6.0% | 0.9—3.1% | |
| Current assets | 210+58.1%95.6% | 133−13.7%94.5% | 154−21.0%98.1% | 195+32.4%97.6% | 147+193%95.7% | 50+91.3%96.7% | 26r0.0—86.4% | |
| Property, plant and equipment | 0.1−71.1%0.0% | 0.4−60.7%0.3% | 0.9−42.7%0.6% | 1.6−30.1%0.8% | 2.2+99.2%1.5% | 1.1−70.0%2.2% | 3.8—12.3% | |
| Right-of-use (leased) assets | 9.1+35.2%4.1% | 6.7+279%4.8% | 1.8−40.1%1.1% | 3.0−27.4%1.5% | 4.1—2.7% | 0—0.0% | — | |
| Total assets | 220+56.4%100% | 140−10.5%100% | 157−21.4%100% | 200+29.8%100% | 154+196%100% | 52+70.9%100% | 30r0.0—100% | |
| Accounts payable | 1.6−29.5%0.7% | 2.2−45.0%1.6% | 4.1+20.9%2.6% | 3.4+290%1.7% | 0.9−18.3%0.6% | 1.1+68.7%2.0% | 0.6r0.0—2.1% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 7.5+33.9%14.4% | 5.6—18.4% | |
| Current liabilities | 14+57.4%6.4% | 8.9+13.8%6.3% | 7.8−51.8%5.0% | 16+52.1%8.1% | 11+5.3%6.9% | 10+2.8%19.5% | 9.8r0.1—32.3% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 1.9−79.9%3.6% | 9.3—30.6% | |
| Lease liabilities (non-current) | 8.8+40.2%4.0% | 6.3+1075%4.5% | 0.5−70.8%0.3% | 1.8−39.7%0.9% | 3.0—2.0% | 0—0.0% | — | |
| Total liabilities | 23+50.3%10.4% | 15+82.0%10.8% | 8.3−53.7%5.3% | 18+31.6%9.0% | 14+14.3%8.9% | 12−37.4%23.1% | 19r0.1—62.9% | |
| Retained earnings | −431—−196% | −365—−260% | −315—−201% | −273—−137% | −234—−152% | −151—−292% | −122r−0.1—−401% | |
| Shareholders' equity | 197+57.1%89.6% | 125−15.7%89.2% | 149−18.2%94.7% | 182+29.7%91.0% | 140+251%91.1% | 40+255%76.9% | 11r−0.1—37.1% | |
| Total liabilities and equity | 220+56.4%100% | 140−10.5%100% | 157−21.4%100% | 200+29.8%100% | 154+196%100% | 52+70.9%100% | 30r0.0—100% | |
| Shares outstanding | 178+29.4%— | 138+8.0%— | 128+1.1%— | 126+25.3%— | 101+96.9%— | 51+628%— | 7.0r5.0—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.3−53.1%— | 0.6−15.7%69.3% | 0.7−10.6%— | 0.8+30.3%— | 0.6−75.0%— | 2.4+14.3%— | 2.1—— | |
| Share-based compensation | 8.4−2.2%— | 8.6+39.9%1007% | 6.1+14.8%— | 5.3+32.3%— | 4.0+0.3%— | 4.0+339%— | 0.9—— | |
| Cash from operating activities | −49—— | −45—−5277% | −41—— | −34—— | −20—— | −27—— | −32—— | |
| Capital expenditure | −0.0—— | −0.0—−5.2% | −0.0—— | −0.2—— | −1.6—— | −0.1—— | −0.5—— | |
| Acquisitions, net of cash acquired | — | — | — | 0—— | −0.3—— | — | — | |
| Cash from investing activities | −93−299%— | 47+73.5%5503% | 27—— | −151—— | −1.8−4758%— | 0.0—— | −0.5—— | |
| Debt repaid | — | — | — | 0—— | −9.4—— | −5.6—— | — | |
| Shares issued | 138+662%— | 18+479%2131% | 3.1−95.9%— | 76−40.6%— | 128+112%— | 60—— | — | |
| Cash from financing activities | 130+648%— | 17+491%2040% | 2.9−96.1%— | 76−36.1%— | 119+144%— | 49—— | — | |
| Change in cash | −13−167%— | 19—2265% | −11—— | −110−213%— | 97+346%— | 22—— | −32—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0*—— | 0—— | 0−100%— | — | 0*—— | 0—— | 0.9—100% | — | 0*—— | |
| Research and development | 69+24.1%— | 22+71.8%— | 20+19.3%— | 13+2.6%— | 14*+4.9%— | 13+48.9%— | 16+46.9%— | 13+37.1%— | 13*+4.9%— | 8.6—— | 11—1315% | 9.5—— | 12*—— | |
| General and administrative | 25+57.8%— | 6.8+126%— | 7.4+59.2%— | 6.9+40.7%— | 4.3*+22.1%— | 3.0−17.5%— | 4.7−1.5%— | 4.9+51.2%— | 3.5*+19.2%— | 3.6—— | 4.7—555% | 3.2—— | 3.0*—— | |
| Operating expenses | 94+31.7%— | 29+82.1%— | 27+28.1%— | 20+13.0%— | 18*+8.5%— | 16+29.2%— | 21+32.5%— | 18+40.7%— | 17*+7.7%— | 12—— | 16—1870% | 13—— | 15*—— | |
| Operating income | −94—— | −29—— | −27—— | −20—— | −18*—— | −16—— | −21—— | −18—— | −17*—— | −12—— | −15—−1770% | −13—— | −15*—— | |
| Interest and finance income | — | — | — | — | — | — | 1.2−40.0%— | 1.3−35.0%— | 1.6*−20.0%— | 1.8—— | 2.0—235% | 2.0—— | 2.0r2.0*—— | |
| Other non-operating income (expense) | 7.7+37.3%— | 1.6+4.6%— | 1.8+54.0%— | 2.0+48.7%— | 2.3*+47.6%— | 1.6−11.4%— | 1.2−39.8%— | 1.3−32.8%— | 1.5*−22.1%— | 1.8—— | 2.0—232% | 2.0—— | 2.0*—— | |
| Income before tax | — | — | — | — | — | — | — | −17—— | — | — | −13—−1538% | −11—— | −13*—— | |
| Income tax | — | — | — | — | — | — | — | 0—— | — | — | 0—0.0% | 0—— | 0*—— | |
| Net income attributable to shareholders | −86—— | −27—— | −25—— | −18—— | −16*—— | −14—— | −20—— | −17—— | −15*—— | −10—— | −13—−1538% | −11—— | −13*—— | |
| Earnings per share, basic | — | -0.15—— | -0.13—— | -0.10—— | — | -0.08—— | -0.14—— | -0.12—— | — | -0.08—— | -0.10—— | -0.08—— | — | |
| Shares, weighted average (basic) | 187+10.7%— | 187+10.7%— | 187+35.1%— | 186+34.8%— | — | 169+22.7%— | 138+0.5%— | 138+1.2%— | — | 138—— | 138—— | 137—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | 138—— | — | 138—— | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 41—23.8% | 41−10.3%23.8% | 35+55.1%18.6% | 55+34.4%26.9% | 31−29.5%14.0% | 46+138%20.0% | 23+17.8%19.6% | 41−5.6%31.2% | 43+79.5%31.0% | 19r37—13.0% | 19—12.5% | 43r24—27.0% | 24—15.4% | |
| Short-term investments | 122—69.7% | 122−30.0%69.7% | 144+84.9%75.9% | 140+94.9%68.0% | 178+114%81.2% | 174+76.1%75.1% | 78−38.4%66.9% | 72−46.0%54.5% | 83−35.1%59.3% | 99—66.1% | 127—81.5% | 133—82.3% | 128—81.7% | |
| Other current assets | 2.4—1.4% | 2.4+99.1%1.4% | 1.0−80.7%0.5% | 1.0−91.3%0.5% | 0.9−84.9%0.4% | 1.2−78.7%0.5% | 5.2−28.3%4.5% | 12+389%8.8% | 6.0+325%4.3% | 5.7—3.8% | 7.3—4.7% | 2.4—1.5% | 1.4—0.9% | |
| Current assets | 165—94.8% | 165−25.2%94.8% | 181+70.3%95.1% | 196+57.6%95.4% | 210+58.1%95.6% | 221+56.7%95.6% | 106−30.8%91.0% | 124−21.7%94.4% | 133−13.7%94.5% | 141—94.6% | 154—98.7% | 159—98.4% | 154—98.1% | |
| Property, plant and equipment | 0.4—0.2% | 0.4+238%0.2% | 0.3+147%0.2% | 0.2+65.7%0.1% | 0.1−71.1%0.0% | 0.1−75.9%0.1% | 0.1−77.9%0.1% | 0.1r0.2−86.3%0.1% | 0.4−60.7%0.3% | 0.5—0.3% | 0.6—0.4% | 0.7—0.5% | 0.9—0.6% | |
| Right-of-use (leased) assets | 8.0—4.6% | 8.0−15.0%4.6% | 8.4−14.4%4.4% | 8.7+34.4%4.3% | 9.1+35.2%4.1% | 9.5+36.0%4.1% | 9.8+750%8.4% | 6.5+344%5.0% | 6.7+279%4.8% | 7.0—4.7% | 1.2—0.7% | 1.5—0.9% | 1.8—1.1% | |
| Total assets | 174—100% | 174−24.5%100% | 190+63.0%100% | 205+56.1%100% | 220+56.4%100% | 231+55.1%100% | 117−25.0%100% | 131−18.4%100% | 140−10.5%100% | 149—100% | 156—100% | 161—100% | 157—100% | |
| Accounts payable | 6.3—3.6% | 6.3+104%3.6% | 2.9+12.0%1.5% | 0.9−42.5%0.4% | 1.6−29.5%0.7% | 3.1+222%1.3% | 2.6+118%2.2% | 1.6+84.7%1.2% | 2.2−45.0%1.6% | 1.0—0.6% | 1.2—0.8% | 0.9—0.5% | 4.1—2.6% | |
| Current liabilities | 24—14.0% | 24+96.3%14.0% | 16+16.4%8.5% | 10−31.0%5.0% | 14+57.4%6.4% | 12+180%5.4% | 14+45.8%11.9% | 15+283%11.3% | 8.9+13.8%6.3% | 4.4—3.0% | 9.5—6.1% | 3.9—2.4% | 7.8—5.0% | |
| Lease liabilities (non-current) | 7.6—4.3% | 7.6−14.4%4.3% | 8.0−17.0%4.2% | 8.4+34.2%4.1% | 8.8+40.2%4.0% | 8.8r9.2+39.7%3.8% | 9.6—8.3% | 6.3+3219%4.8% | 6.3+1075%4.5% | 6.3—4.2% | 0—0.0% | 0.2—0.1% | 0.5—0.3% | |
| Total liabilities | 32—18.3% | 32+47.5%18.3% | 24+2.7%12.7% | 19−11.7%9.1% | 23+50.3%10.4% | 22+101%9.4% | 23+147%20.1% | 21+419%16.1% | 15+82.0%10.8% | 11—7.2% | 9.5—6.1% | 4.1—2.5% | 8.3—5.3% | |
| Retained earnings | −502—−288% | −502—−288% | −475—−250% | −449—−219% | −431—−196% | −415—−180% | −401—−344% | −381—−290% | −365—−260% | −350—−234% | −339—−218% | −326—−202% | −315—−201% | |
| Shareholders' equity | 143—81.7% | 143−32.0%81.7% | 166+78.2%87.3% | 186+69.1%90.9% | 197+57.1%89.6% | 210+51.5%90.6% | 93−36.2%79.9% | 110−29.8%83.9% | 125−15.7%89.2% | 138—92.8% | 146—93.9% | 157—97.5% | 149—94.7% | |
| Total liabilities and equity | 174—100% | 174−24.5%100% | 190+63.0%100% | 205+56.1%100% | 220+56.4%100% | 231+55.1%100% | 117−25.0%100% | 131−18.4%100% | 140−10.5%100% | 149—100% | 156—100% | 161—100% | 157—100% | |
| Shares outstanding | 180—— | 180+1.4%— | 180+30.2%— | 180+30.2%— | 178+29.4%— | 178+29.1%— | 138+0.5%— | 138+0.5%— | 138+8.0%— | 138—— | 138—— | 138—— | 128—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−79.7%— | 0.0*+47.4%— | 0.0*−79.0%— | 0.0−89.3%— | 0.0*−87.9%— | 0.0*−86.7%— | 0.1*−34.2%— | 0.1−9.1%— | 0.1*−13.0%— | 0.1*—— | 0.2*—17.9% | 0.2—— | 0.2*—— | |
| Share-based compensation | 16+79.1%— | 4.0+224%— | 4.8+72.8%— | 5.1+102%— | 1.8*−18.5%— | 1.2−43.7%— | 2.8+31.6%— | 2.5+25.5%— | 2.2*+39.9%— | 2.2—— | 2.1—250% | 2.0—— | 1.6*—— | |
| Cash from operating activities | −62—— | −16*—— | −15*—— | −17—— | −13*—— | −11*—— | −12*—— | −13—— | −9.2*—— | −11*—— | −11*—−1265% | −14—— | −12*—— | |
| Capital expenditure | −0.4—— | −0.1*—— | −0.2*—— | −0.1—— | 0*—— | −0.0*—— | 0*—— | −0.0—— | 0*—— | −0.0*—— | 0*—0.0% | 0—— | −0.0*—— | |
| Cash from investing activities | 52—— | 22*—— | −5.0*—— | 38+232%— | −3.4*−122%— | −95*−428%— | −6.4*−198%— | 12—— | 15*+143%— | 29*—— | 6.5*—763% | −4.1—— | 6.3*—— | |
| Shares issued | — | — | — | — | 0*—— | 138*—— | 0*—— | 0−100%— | 0*—— | 0*—— | 0*—0.0% | 18—— | 0*—— | |
| Cash from financing activities | 4.4−96.6%— | 0*−100%— | 0*—— | 3.4—— | 1.1*—— | 129*—— | 0*−100%— | −0.8−105%— | −0.1*—— | −0.0*—— | 0.0*—0.1% | 17—— | −0.2*—— | |
| Change in cash | −4.7−154%— | 6.0*−74.2%— | −20*—— | 25—— | −16*−355%— | 23*+30.0%— | −18*—— | −2.4—— | 6.1*—— | 18*—— | −4.3*—−502% | −0.6—— | −6.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Compass Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Thomas Schuetz | $5.1 M | $11.4 M | $1.4 M | $344 |
| 2024Thomas J. Schuetz | $6.4 M | $6.8 M | $1.1 M | $93 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Compass Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 2 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Compass Therapeutics, Inc.#
$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2025
Todd Strategy Group $80 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2025 | $80 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Compass Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Compass Therapeutics, Inc. compares in Biotechnology
- Market cap$137 M · higher than 40% of 726
- Revenue$0 M · higher than 0% of 647
- Price / book0.7× · lower than 85% of 534
- FCF yield-35.9% · higher than 31% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Compass Therapeutics, Inc.🇺🇸 | $137 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing, SEC annual report.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Compass Therapeutics, Inc.? Verify and update this profile — free
Show Compass Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.